Factor XIII is one of the twelve coagulation factors and also known as a fibrin-stabilizing factor. In 2012, we encountered a male RA patient with hemorrhagic factor XIII deficiency who had been treated with tocilizumab for two years. There are few reports regarding the relationship between tocilizumab (a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R)) and factor XIII....

background: recurrent pregnancy loss is (rpl) a heterogeneous condition. while the role of acquired thrombophilia has been accepted as an etiology for rpl, the contribution of specific inherited thrombophilic gene polymorphisms to the disorder has been remained controversial. methods: one hundred women with a history of two or more consecutive abortions and 100 women with at least two live birt...

The binding of plasma factor XIII to fibrinogen or fibrin that has been chemically or enzymatically induced to polymerize was studied. Factor XIII binding was assayed using a 3H-putrescine incorporation assay and an 125I-plasma factor XIII binding assay. More than 80% of the native and radiolabeled plasma factor XIII was bound to fibrin I formed by reptilase in EDTA, citrate, or heparin anticoa...

Factor XIII (Fibrin-stabilizing factor) is a tetrameric structural pro-transglutaminase from the transglutaminase family. Factor XIII activity is associated with the structure of fibrin clot. Factor XIII turns into XIII-A, which is an active transglutaminase, in the result phase of coagulation cascade together with Ca and thrombin activation. The main aim of Factor XIIIA is to connect ε(δ-gluta...

Thrombin cleavage of blood coagulation Factor XIII (a2b2) and fibrinogen was studied during in vitro clotting to determine the physiologic sequence of these events. First, the time course of fibrin formation and cleavage of Factor XIII was measured in platelet-rich plasma. Cleavage of fibrinogen was measured by using a radioimmunoassay for fibrinopeptide A. Conversion of trace amounts of radioi...

These studies examined the fate of Factor XIII (fibrin-stabilizing factor) in mice with plasmacytoma (MOPC-300, MOPC-384, MOPC-467, and J-558). Plasma Factor XIII levels in these mice decreased progressively with tumor expansion. No plasma inhibitors of Factor XIII activity could be detected. Factor XIII was found on plasmacytoma cell membranes and in the cytoplasm of the malignant cells by imm...

In the blood coagulation cascade, thrombin cleaves fibrinopeptides A and B from fibrinogen revealing sites for fibrin polymerization that lead to insoluble clot formation. Factor XIII stabilizes this clot by catalyzing the formation of intermolecular cross-links in the fibrin network. Thrombin activates the Factor XIII a(2) dimer by cleaving the Factor XIII activation peptide segment at the Arg...

Antibodies to factor XIII have not been Antisera to ‘yG2, i G3, ‘yG4, ‘yA, ‘yM, previously characterized in detail. An ac‘yD, ‘yE, and k light-chains had no detectquired inhibitor to factor XIII, which develable effect. Preparative zone electrooped in a patient following thrombectomy phoresis revealed the inhibitor to be in for a femoral artery occlusion, has been the cathodal portion of the ga...

The effect of factor XIII on endothelial barrier function was studied in a model of cultured monolayers of porcine aortic endothelial cells and saline-perfused rat hearts. The thrombin-activated plasma factor XIII (1 U/ml) reduced albumin permeability of endothelial monolayers within 20 min by 30 +/- 7% (basal value of 5.9 +/- 0.4 x 10(-6) cm/s), whereas the nonactivated plasma factor XIII had ...